GlassScriptPhysician profile
Samuel Alfano
NPI 1588764872
$635.02
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $113 · 2021: $165 · 2022: $184.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $223.73 | 2019-2022 | |
| Lilly USA, LLC | $115.35 | 2019-2022 | |
| Abbvie INC. | $65.83 | 2021 | |
| Glaxosmithkline, LLC. | $57.81 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $43.64 | 2022 | |
| Janssen Pharmaceuticals, INC | $35.52 | 2021-2022 | |
| Pfizer INC. | $24.81 | 2019-2022 | |
| Boston Scientific Corporation | $19.91 | 2022 | |
| Amarin Pharma, INC. | $18.55 | 2020 | |
| Merck Sharp & Dohme LLC | $15.05 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.82 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Alfano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.